Pharmacy’s role in cardiovascular risk from antipsychotic medicines
Antipsychotic medications can improve symptoms of psychosis, bipolar disorder and other mental health conditions, but they may also affect cardiometabolic health. Weight gain, raised blood glucose, dyslipidaemia and hypertension can develop early after treatment begins. The physical effects may be subtle, while the medicines themselves can be essential to recovery and must not be stopped without appropriate clinical advice. Learn more about 404994 Creating A Tobacco Cessation Referral Pathway Between Community Pharmacies And Primary Care.
The role of pharmacy in mitigating the cardiovascular risks of antipsychotic medications is therefore broader than dispensing. Community pharmacists are accessible health professionals who see patients frequently, recognise changes in weight, blood pressure and lifestyle, and can connect medication concerns with primary care. In Australia, this work occurs within a system shaped by the Therapeutic Goods Administration, the Pharmaceutical Benefits Scheme and Medicare-funded clinical services.
Why cardiovascular risk changes after prescribing
Antipsychotics can influence appetite, energy expenditure, insulin sensitivity and lipid metabolism. Olanzapine and clozapine carry substantial weight and metabolic risks, while aripiprazole and lurasidone generally have a lower metabolic burden. Individual risk still varies, and medication choice should account for baseline weight, blood pressure, glucose control, smoking status, age and existing cardiovascular disease.
Some medicines also affect heart rhythm, blood pressure or orthostatic tolerance. QT interval prolongation is relevant for certain antipsychotics, particularly when QT-prolonging medicines are combined. Antihypertensive drugs, diuretics and sedatives may increase dizziness or falls. These effects do not automatically require discontinuation, but they should trigger a structured review rather than an informal reassurance.
Cardiovascular disease often develops through several mechanisms at once. A person may experience weight gain, reduced physical activity, poor diet, smoking, sleep disruption and difficulty maintaining treatment routines. Mental health symptoms can make appointments, exercise and healthy eating harder, meaning a conventional prevention message without practical support may have little effect.
What community pharmacists can assess at the counter
Every antipsychotic repeat dispensing creates an opportunity to ask brief, respectful questions about weight change, thirst, urination, dizziness, palpitations, breathing difficulties and reduced exercise tolerance. Medication records can also reveal clinically important combinations, recent changes in dose and medicines associated with metabolic or cardiac adverse effects.
Where equipment and privacy are available, pharmacists can measure weight, waist circumference and blood pressure and compare results with previous observations. Blood pressure should be measured using an appropriate cuff and correct technique, with seated and standing readings considered when orthostatic symptoms are present. In Melbourne and Sydney, many community pharmacies offer private consultation spaces, while regional pharmacies may work through local general practices or Aboriginal health services.
Screening creates a duty to act on abnormal findings. Pharmacists should document measurements, explain their significance and seek agreement about referral. If a person reports chest pain, severe breathlessness, syncope or a concerning irregular heartbeat, urgent medical assessment is appropriate. Less urgent findings can be sent to the patient’s general practitioner, nurse or psychiatrist using an agreed process.
Turning medication review into cardiovascular prevention
A cardiovascular medication review should connect the antipsychotic prescription with the rest of the patient’s medicines and health history. This includes checking adherence, injection technique where relevant, over-the-counter medicines, complementary products, alcohol use, smoking and other substances. Reviewing the actual medicine, rather than relying only on a dispensing history, can reveal problems that remain invisible in administrative records.
Clinical measurements should be interpreted alongside laboratory results such as lipid profile, HbA1c or fasting glucose, and kidney function. The prescriber may also need to consider an ECG, particularly for people with cardiac disease, syncope or additional QT-prolonging medicines. Baseline and follow-up monitoring should follow current product information and Australian guidance, with greater attention during the first months of treatment or after a dose change.
For patients with complex conditions, an accredited pharmacist may provide a Home Medicines Review funded through Medicare after general practitioner referral. This service can identify adverse effects, interactions and barriers to adherence that are difficult to address in a short consultation. The review is most valuable when its recommendations reach both the patient and the treating clinicians, rather than remaining filed as a separate report.
Supporting metabolic health and tobacco cessation
Weight management should be framed as treatment support, not blame. Pharmacists can work with dietitians, exercise physiologists, diabetes educators and general practitioners to develop achievable changes that fit the person’s health, income and daily routines. A small increase in walking, reduced high-salt foods or regular meal planning may be more useful than broad advice to “eat better and exercise”.
Smoking is both a major cardiovascular risk and a common issue among people with severe mental illness. Pharmacy-based cessation support can combine counselling, nicotine replacement therapy and referral to quit services. A useful model is described in this guide to tobacco cessation referrals, which emphasises clear relationships between community pharmacies and primary care.
Smoking changes require particular medication vigilance because tobacco smoke affects the metabolism of some antipsychotics. For example, increased or reduced smoking while taking clozapine or olanzapine can alter drug concentrations and toxicity risk. Conversely, stopping smoking may cause weight gain, so cessation support should include both metabolic monitoring and realistic expectations. Pharmacists can also use pharmacist health coaching to turn clinical priorities into patient-selected goals.
Building closed-loop collaboration with care teams
Referral is not complete until the receiving clinician has received the information and responded. A useful pathway defines who checks blood pressure, who orders laboratory tests, who reviews an ECG and how a person is contacted after an abnormal result. This may involve the patient’s general practitioner, psychiatrist, cardiologist, diabetes team, mental health nurse and Aboriginal Health Practitioner.
Consent should guide information sharing, especially when a person sees several services. With permission, pharmacists can use electronic prescribing, pathology results and shared clinical records, but local agreements remain important where systems do not connect. Telephone follow-up can be more effective than sending a letter the patient may not have the capacity or resources to act upon.
Collaboration should also address access. Medicare-funded cardiovascular health assessments by general practitioners can support risk calculation, while pharmacy services provide frequent contact between formal appointments. In Aboriginal and remote communities, pharmacists can work with Aboriginal Community Controlled Health Services and culturally safe teams to ensure that prevention is accessible, locally governed and not undermined by travel or distance.
Mental illness, suicide risk and compassionate monitoring
People with severe mental illness experience higher rates of cardiovascular disease, partly because of smoking, inactivity, metabolic effects, poverty, discrimination and fragmented healthcare. A focus on physical health can sometimes feel like judgment or another demand placed on the patient. Monitoring should therefore be private, explained clearly and connected to practical support.
Resources such as suicide prevention information can help pharmacists recognise warning signs, ask directly about safety and provide appropriate support contacts. If a patient appears to be in immediate danger or has taken an overdose, emergency action is required. In Australia, call 000, while Lifeline on 13 11 14 offers confidential support around the clock, and healthdirect on 1800 022 222 provides clinical advice.
Compassionate monitoring does not mean avoiding difficult conversations. A person may value antipsychotic treatment but feel overwhelmed by weight gain, fatigue or financial cost. Exploring which problem matters most can preserve the therapeutic relationship and lead to prescriber review, supportive care or adjusted goals. Where capacity is affected, the pharmacist should involve the appropriate substitute decision-maker while continuing to hear the patient’s own concerns.
A practical pathway for safer prescribing
A dependable service needs agreed procedures rather than reliance on individual enthusiasm. The pathway should include risk identification, consent, measurement, referral, follow-up and escalation. Staff need training in physical assessment, mental health conversations, cultural safety and trauma-informed care. Private space, suitable equipment and access to pathology or general practice support can determine whether the pathway works in practice.
Quality measures should capture more than the number of blood pressure checks completed. Useful measures include abnormal results followed up, referrals accepted by primary care, smoking cessation support offered, and whether patients report that their concerns were heard. Services should also examine whether monitoring reaches people experiencing homelessness, limited English proficiency or disability. Pharmacy leaders can use local needs and state scope-of-practice requirements to build a model that fits the community.
The Pharmaceutical Benefits Scheme creates continuing contact with antipsychotic users, while the Therapeutic Goods Administration’s product information and safety communications provide essential information for monitoring. Practices, community pharmacies and policymakers can use these systems to make cardiovascular review routine, funded and coordinated with mental health care. Make the cardiovascular review of every antipsychotic prescription a standard part of community care, with pharmacists acting as active partners in protecting the heart and the mind.